newsfilter
← Latest News
PR Newswire·

Bausch Health's Gastroenterology Business, Salix, to Present New Data on Cirrhosis Trends and Severe Alcohol-Associated Hepatitis at The Liver Meeting® 2026

BHC
  • Bausch Health Companies Inc. & its GI business Salix Pharmaceuticals presented a research poster at The Liver Meeting 2026 in Denver from November 5–9, 2026.
  • The study evaluated 1,630 adults in the U.S. hospitalized with severe alcohol-associated hepatitis (AH).
  • Estimated overall survival at 12 months was 62.0% for the cohort.
  • Rehospitalization occurred in 31.4% of patients within 30 days of discharge & was estimated at 69.1% by 12 months.
  • The estimated liver transplantation rate at 12 months was 8.5%.
  • Jonathan Sadeh, Executive Vice President, Chief Medical Officer & Head of R&D at Bausch Health, emphasized the substantial burden of advanced liver disease & the urgent unmet need for effective therapies.
  • The findings highlight the need for improved management strategies & real-world evidence to inform research priorities for severe AH.
Company
Bausch Health Companies Inc.
Keywords
Bausch Health Companies Inc.